Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
15.65
+0.03 (0.19%)
At close: Oct 7, 2025, 4:00 PM EDT
15.59
-0.06 (-0.38%)
After-hours: Oct 7, 2025, 4:41 PM EDT
Keros Therapeutics Revenue
Keros Therapeutics had revenue of $18.17M in the quarter ending June 30, 2025, with 49,002.70% growth. This brings the company's revenue in the last twelve months to $232.84M, up 85,820.30% year-over-year. In the year 2024, Keros Therapeutics had annual revenue of $3.55M with 2,250.99% growth.
Revenue (ttm)
$232.84M
Revenue Growth
+85,820.30%
P/S Ratio
2.67
Revenue / Employee
$1,377,775
Employees
169
Market Cap
635.63M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.55M | 3.40M | 2,250.99% |
Dec 31, 2023 | 151.00K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | 20.10M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
KROS News
- 4 weeks ago - Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - GlobeNewsWire
- 6 weeks ago - ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment - PRNewsWire
- 6 weeks ago - Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 2 months ago - Keros to Exclusively Prioritize the Clinical Advancement of KER-065 - GlobeNewsWire
- 2 months ago - Keros Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept - GlobeNewsWire
- 4 months ago - ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal - PRNewsWire